The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | DEDICATION-1: reduced versus standard dose pembrolizumab in stage IV NSCLC
Mariana Brandão, MD, PhD, Jules Bordet Institute, Brussels, Belgium, comments on the interim results from the DEDICATION-1 trial (NCT04909684) of reduced-dose pembrolizumab compared to standard dosing in patients with non-small cell lung cancer (NSCLC). The study evaluates pembrolizumab as monotherapy or in combination with chemotherapy. The interim analysis showed no significant difference in one-year overall survival or progression-free survival between reduced and standard dosing, supporting the trial’s continuation. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
